News | February 07, 2024
IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
The facility will have a capacity to manufacture upto 3 million tubes monthly
Subscribe To Our Newsletter & Stay Updated
